Navigation Links
Kendle Director of Global Safety and Pharmacovigilance, Drew Kilpatrick, PhD, Named One of Ten 'Notable People in R&D'
Date:3/23/2010

CINCINNATI, March 23 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced Drew Kilpatrick, PhD, Director, Global Safety and Pharmacovigilance, has been named one of ten "Notable People in R&D" by leading industry publication R&D Directions.  Dr. Kilpatrick was selected based on his pioneering work in developing TrialEAS™, a practical Web-based solution that enables independent adjudication of clinical endpoints and assists investigators in selecting appropriate patients for enrollment into clinical studies.  TrialEAS™ recently was honored as the "Best Technological Development in Clinical Trials – Software Solution" at the 2009 Clinical Research Excellence Awards sponsored by Good Clinical Practice Journal.

"We are so pleased that R&D Directions has recognized the groundbreaking and innovative nature of the work completed by Dr. Kilpatrick and his team," said Stephen Cutler, PhD, Senior Vice President and Chief Operating Officer.  "As regulatory authorities increase requirements for endpoint driven studies to confirm morbidity, mortality or safety, it becomes ever more crucial to develop solutions that reduce costs within the clinical development process without compromising patient safety or clinical judgment.  With TrialEAS™, Dr. Kilpatrick's team has introduced a versatile Web-based solution that fulfills these requirements."    


'/>"/>
SOURCE Kendle International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Kendle Executive to Share Insights at World Pharma Trials Asia 2010
2. Kendle is First Global CRO to Achieve ISO 9001:2008 Certification in China Through Beijing Affiliate
3. Kendle Launches New Global Biostatistics Infrastructure
4. Kendle Receives Approval From Indian Government to Proceed With Development of Operations Center in Special Economic Zone
5. Kendle Appoints J. Michael Sprafka, MPH, PhD, Vice President, Kendle Consulting
6. Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
7. Kendle Experts to Share Insights at the Regulatory Affairs Professionals Society Annual Conference and Exhibition
8. Kendle Experts to Present at the Drug Information Association 44th Annual Meeting
9. Kensey Nash Corporation Announces the Addition of Donald Morel, Jr., Ph.D. to Its Board of Directors
10. ThermalTherapeutic Systems, Inc. Announces the Addition of Former MEDRAD Executive Alan Hirschman, PhD to the Board of Directors
11. Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... LOS ANGELES, May 1, 2015  CytRx Corporation ... in oncology, today reported financial results for the ... an overview of recent accomplishments and upcoming milestones ... achieved several milestones in the early months of ... its clinical trial of aldoxorubicin in patients with ...
(Date:5/1/2015)... MARLBOROUGH, Mass. , May 1, 2015  Boston ... overview of its continued business momentum and long-term growth ... in New York City . President ... outline the unique opportunities the company has to bring ... into fast growing markets and deliver shareholder value. ...
(Date:5/1/2015)...  Shares of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI ... the results of the Phase 3 Rocket 1 trail ... failing to meet its end points, compelling data from ... future studies. An analyst report on AERI ... review, analyst summary, valuation, and recommendation can be viewed ...
Breaking Medicine Technology:CytRx Reports First Quarter 2015 Financial Results 2CytRx Reports First Quarter 2015 Financial Results 3CytRx Reports First Quarter 2015 Financial Results 4CytRx Reports First Quarter 2015 Financial Results 5CytRx Reports First Quarter 2015 Financial Results 6CytRx Reports First Quarter 2015 Financial Results 7CytRx Reports First Quarter 2015 Financial Results 8CytRx Reports First Quarter 2015 Financial Results 9CytRx Reports First Quarter 2015 Financial Results 10CytRx Reports First Quarter 2015 Financial Results 11Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2
... Phase 3 Once Weekly Investigational Diabetes Therapy Also Improved ... from Exenatide Taken Twice a Day, SAN FRANCISCO, ... Eli Lilly and Company (NYSE: LLY ), and ... a 52-week open-label clinical,study that showed the durable efficacy ...
... VIEW, Calif., June 9 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... Phase 2a proof-of-concept clinical trial with AZ-002 (Staccato(R),alprazolam) ... not meet its two,primary endpoints, which were the ... panic attack and the effect of AZ-002 on ...
Cached Medicine Technology:After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 2After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 3After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 4After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 5After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 6After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 7After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 8After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 9Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 2Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 3Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 4
(Date:5/4/2015)... Missouri (PRWEB) May 04, 2015 “St. ... as the “Gateway to the West,” so it is ... for Veterans Program”, says Dr. Ben Litalien, Chief Development ... Franchise Association’s VetFran program and will provide veterans with ... , Zerorez® is proud to have a number of ...
(Date:5/3/2015)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 03, ... reached the 2,000 ‘Like’ mark on their Facebook page. ... that educate the patients on the many services the ... as well as current events. , Women’s Excellence has ... Facebook, Twitter, Google +, Pinterest, Instagram and You Tube. ...
(Date:5/3/2015)... 03, 2015 “ BolehVPN ” was featured ... features the latest and coolest technology products available to consumers. ... conducted the review and shared with viewers how to protect ... these days is on computers and even more so online. ... meet people all over the world. In terms of work, ...
(Date:5/3/2015)... May 03, 2015 HealthPostures, a ... solutions, announces its appearance at the , May 5 ... that HealthPostures will exhibit at the conference include its ... sit stand solutions is the 6100 TaskMate Executive. Features ... control, an adjustable keyboard tray, extended platform work surface ...
(Date:5/2/2015)... CA (PRWEB) May 02, 2015 ProText Kinetic ... for use in Final Cut Pro X. ProText Kinetic ... use in Final Cut Pro X . Easily ... keyframe with Pixel Film Studios' ProText Kinetic 2. , Using ... Start by staggering two ProText Kinetic presets in the FCPX ...
Breaking Medicine News(10 mins):Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 3Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2
... to Medicare payments are intended to accurately and equitably ... incurred by hospitals and individual health care practitioners, but ... to how their adjustments are calculated, finds a new ... of exceptions strongly suggests that the mechanisms underlying the ...
... advocacy organizations from India, Australia and the United States ... for the Study of Lung Cancer (IASLC) to send ... July 3-7 in Amsterdam. The winners are: ... Foundation is the premier organization for lung health in ...
... treatment for patients with advanced non-small cell lung ... cytotoxic chemotherapy drugs. The combination, however, comes with ... report that a combination of two molecularly-targeted agents ... "These results seem to be better than ...
... BOSTONScientists at Dana-Farber Cancer Institute have identified an ... breast cancer cells enriched in triple-negative breast tumors, ... to current therapies. Kornelia Polyak, MD, PhD, ... found that a large proportion of cells within ...
... Reporter , WEDNESDAY, June 1 (HealthDay News) -- Beta blockers ... by millions of people -- may eventually have a role ... One study suggests that women who are already taking beta ... breast cancer at an earlier stage of the disease and ...
... heart failure, an implanted mechanical pump known as a ... treatment. Even though the technology involves risks, few patients ... "what ifs" before surgery takes place. In the June ... of Mayo Clinic researchers found that careful discussions at ...
Cached Medicine News:Health News:Medicare should employ new data sources, methods to ensure accuracy of geographic adjustments to payments 2Health News:Medicare should employ new data sources, methods to ensure accuracy of geographic adjustments to payments 3Health News:5 advocacy organizations win travel awards to attend World Conference on Lung Cancer in Amsterdam 2Health News:5 advocacy organizations win travel awards to attend World Conference on Lung Cancer in Amsterdam 3Health News:Less toxic combination of erlotinib and bevacizumab is effective non-small cell lung cancer patients 2Health News:Scientists identify overactive genes in aggressive breast cancers 2Health News:Widely Used Heart Drugs Linked to Better Breast Cancer Outcomes 2Health News:Widely Used Heart Drugs Linked to Better Breast Cancer Outcomes 3Health News:Mayo Clinic finds discussion of end-of-life care helps heart to patients and families 2
Round serrated handle, dull finish....
Cross action, round handle, maximum opening 2.8 mm....
Cross action, round handle, maximum opening 2.8 mm....
Cross action, round handle, maximum opening 2.8 mm....
Medicine Products: